SCHEMBL1987167

SCHEMBL1987167

O=C(NC(NC(=O)c1c(O)c2cccn2n(Cc2ccccc2)c1=O)C(=O)O)c1c(O)c2cccn2n(Cc2ccccc2)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.42
KDM4E B2RXH2 3/20 0.41
HTT P42858 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HIF1A Q16665 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
BRD4 O60885 1/20 0.37
BRD2 P25440 1/20 0.37
BRD3 Q15059 1/20 0.37
BRDT Q58F21 1/20 0.37
EGLN3 Q9H6Z9 1/20 0.36
LMNA P02545 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968949 0.83 EGLN1 (0.61) EGLN1MEN1KMT2ARAB9ANPC1
SCHEMBL1976397 0.82 POLB (0.47) KDM4EHTTALDH1A1MEN1KMT2A
SCHEMBL1980308 0.81 TDP1 (0.50) KDM4EHTTALDH1A1MEN1KMT2A
SCHEMBL1966102 0.79 KDM4E (0.43) EGLN1KDM4EHTTALDH1A1MEN1
SCHEMBL1966106 0.79 KDM4E (0.43) EGLN1KDM4EHTTALDH1A1MEN1
SCHEMBL1970302 0.77 KDM4E (0.42) EGLN1KDM4EHTTALDH1A1EGLN3
SCHEMBL1967350 0.76 KDM4E (0.54) KDM4EHTTALDH1A1MEN1KMT2A
SCHEMBL1965787 0.76 EGLN1 (0.53) EGLN1HIF1AMEN1KMT2AEGLN3
SCHEMBL1968936 0.75 EGLN1 (0.52) EGLN1HIF1AMEN1KMT2AL3MBTL1
SCHEMBL1969894 0.75 EGLN1 (0.52) EGLN1HIF1AEGLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 EGLN1 5/4885KDM4E 471/4885HTT 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.